2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2803 Impact of obesity on time to next treatment and treatment-emergent toxicity in newly diagnosed multiple myeloma treated with daratumumab-vrd: A real-world trinetx analysis

Love Kumar, MD, Baqir Jafry2, Farzeen Fatma Syed, MD3, Talia Alexander4, Amir Kamran, MD5
1 Charleston Area Medical Centre, Charleston, West Virginia, United States
2 Charleston Area Medical Centre, Charleston, West Virginia, United States
3 Charleston Area Medical Centre, Charleston, West Virginia, United States
4 Charleston Area Medical Centre, Charleston, West Virginia, United States
5 Charleston Area Medical Centre, Charleston, West Virginia, United States
Background: Daratumumab plus bortezomib, lenalidomide, and dexamethasone (Dara-VRd) is now a frontline standard of care for transplant-eligible newly diagnosed multiple myeloma (NDMM), yet the influence of obesity on its real-world efficacy and toxicity is undefined. Obesity (body mass index [BMI] >=30 kg/m2) is highly prevalent in MM, promotes pro-inflammatory and pro-tumorigenic signaling, and is an independent venous thromboembolism (VTE) risk factor in IMWG and NCCN guidance that may compound the thrombotic risk of lenalidomide. Prior analyses, almost entirely in pre-quadruplet cohorts, conflict, including reports of an "obesity paradox" in survival. To our knowledge, no study has examined obesity-specific outcomes with frontline Dara-VRd. We evaluated whether obesity modifies time to next treatment (TTNT) and treatment-emergent toxicity.

Methods: Using the TriNetX US Collaborative Network, we identified adults with NDMM receiving Dara-VRd as initial systemic therapy between May 1st 2020 and April 30th 2026 with a baseline BMI recorded; index was the first Dara-VRd administration. Patients were obese (BMI >=30 kg/m2; n=258) or non-obese (BMI 18.5-29.99 kg/m2; n=542). Before matching, obese patients were younger (mean age 61.2 vs 64.3 years) and more often hypertensive (51.6% vs 42.1%). Cohorts were 1:1 propensity score matched on age, sex, race, ethnicity, hypertension, hyperlipidemia, type 2 diabetes, chronic kidney disease, coronary artery disease, cerebrovascular disease, liver disease, and nicotine dependence. After matching (n=245 each), all covariates were balanced (maximum standardized difference 0.09). TTNT was time from index to first pomalidomide, carfilzomib, isatuximab, selinexor, or CAR T-cell therapy, assessed with all-cause mortality over 2 years; toxicities over 1 year; all-cause hospitalization over 30 days. Given low individual event counts, infections were analyzed as overall, serious/opportunistic (sepsis/bacteremia, invasive fungal, Pneumocystis, hepatitis B, cytomegalovirus), and common (respiratory, influenza, pneumonia, herpes zoster, urinary) composites. Kaplan-Meier estimates, log-rank tests, and hazard ratio (HR) estimates were used for time-to-event outcomes and risk ratios (RR) for binary outcomes.
Results: Obese patients had a significantly longer TTNT than non-obese patients (21 vs 37 events; HR 0.53, 95% CI 0.31-0.90; log-rank p=0.017). Two-year freedom from next-line therapy was 88.7% vs 80.4%; median TTNT was not reached in either cohort and the proportional hazards assumption was satisfied (p=0.56). Mortality was similar between cohorts, suggesting the TTNT difference was not explained by differences in overall survival (13 vs 14 deaths; 2-year survival 93.0% vs 92.1%; HR 0.89, 95% CI 0.42-1.89; p=0.76). Among evaluated toxicities, the largest numerical increase in obese patients was observed for VTE. One-year VTE occurred in 8.8% vs 4.5% (RR 1.93, 95% CI 0.95-3.92; risk difference +4.2%, p=0.06) - a near-doubling that did not reach significance at this sample size. Peripheral neuropathy (24.6% vs 20.9%; RR 1.17, 95% CI 0.84-1.64) and 30-day all-cause hospitalization (7.3% vs 4.9%; RR 1.50, 95% CI 0.74-3.05) were also numerically higher. Infectious burden did not differ: overall 31.4% vs 35.9% (RR 0.88), serious/opportunistic 18.4% vs 18.0% (RR 1.02), common 23.3% vs 26.9% (RR 0.86); all p>=0.29.

Conclusions: In this first real-world analysis of obesity-specific outcomes with frontline Dara-VRd, obesity was associated with a 47% lower hazard of requiring next-line therapy over 2 years with no offsetting mortality difference, a pattern consistent with the obesity paradox described in earlier myeloma cohorts that appears to persist in the quadruplet era. Infectious toxicity was comparable across BMI strata, but obese patients experienced a near-doubling of 1-year VTE despite contemporary thromboprophylaxis, a magnitude that is clinically relevant even though the confidence interval crossed unity at this sample size. Limitations include absent ISS stage, cytogenetic risk, response depth, and transplant/maintenance data, possible incomplete ascertainment of next-line therapy outside contributing organizations, and residual confounding. These data suggest obesity does not compromise the durability of frontline quadruplet therapy, support heightened thromboprophylaxis vigilance in obese patients receiving Dara-VRd, and warrant confirmation in disease-risk-annotated cohorts.
Love Kumar, MD: No relevant conflicts of interest to declare.